INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 160 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $2,000 | +100.0% | 100 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | -66.7% | 100 | -52.8% | 0.00% | -100.0% |
| Q4 2019 | $3,000 | +50.0% | 212 | +39.5% | 0.00% | 0.0% |
| Q3 2019 | $2,000 | 0.0% | 152 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $2,000 | -33.3% | 152 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $3,000 | -25.0% | 152 | -42.4% | 0.00% | -50.0% |
| Q4 2018 | $4,000 | -42.9% | 264 | +12.8% | 0.00% | -33.3% |
| Q3 2018 | $7,000 | +16.7% | 234 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $6,000 | +20.0% | 234 | -6.0% | 0.00% | +50.0% |
| Q1 2018 | $5,000 | 0.0% | 249 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $5,000 | -16.7% | 249 | 0.0% | 0.00% | -33.3% |
| Q3 2017 | $6,000 | +50.0% | 249 | 0.0% | 0.00% | +50.0% |
| Q2 2017 | $4,000 | +33.3% | 249 | +0.4% | 0.00% | 0.0% |
| Q1 2017 | $3,000 | 0.0% | 248 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $3,000 | -91.9% | 248 | -88.5% | 0.00% | -92.3% |
| Q3 2016 | $37,000 | – | 2,151 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
| Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
| Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
| MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
| ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
| Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
| Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
| Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
| Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |